Your browser doesn't support javascript.
loading
Design, synthesis, and In vitro antituberculosis activity of 2(5H)-Furanone derivatives.
Ngwane, Andile H; Panayides, Jenny-Lee; Chouteau, Franck; Macingwana, Lubabalo; Viljoen, Albertus; Baker, Bienyameen; Madikane, Eliya; de Kock, Carmen; Wiesner, Lubbe; Chibale, Kelly; Parkinson, Christopher J; Mmutlane, Edwin M; van Helden, Paul; Wiid, Ian.
Afiliação
  • Ngwane AH; Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, SAMRC Centre for TB Research, DST-NRF Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Tygerberg, Cape Town, South Africa.
  • Panayides JL; CSIR Biosciences, Pioneering Health Sciences, Pretoria, South Africa.
  • Chouteau F; Department of Chemistry, University of Cape Town, Rondebosch, South Africa.
  • Macingwana L; Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, SAMRC Centre for TB Research, DST-NRF Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Tygerberg, Cape Town, South Africa.
  • Viljoen A; Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, SAMRC Centre for TB Research, DST-NRF Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Tygerberg, Cape Town, South Africa.
  • Baker B; Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, SAMRC Centre for TB Research, DST-NRF Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Tygerberg, Cape Town, South Africa.
  • Madikane E; Department of Clinical Laboratory Sciences, Division of Medical Microbiology, University of Cape Town, Rondebosch, South Africa.
  • de Kock C; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa.
  • Wiesner L; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa.
  • Chibale K; Department of Chemistry, University of Cape Town, Rondebosch, South Africa.
  • Parkinson CJ; CSIR Biosciences, Pioneering Health Sciences, Pretoria, South Africa.
  • Mmutlane EM; CSIR Biosciences, Pioneering Health Sciences, Pretoria, South Africa.
  • van Helden P; Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, SAMRC Centre for TB Research, DST-NRF Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Tygerberg, Cape Town, South Africa.
  • Wiid I; Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, SAMRC Centre for TB Research, DST-NRF Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Tygerberg, Cape Town, South Africa.
IUBMB Life ; 68(8): 612-20, 2016 08.
Article em En | MEDLINE | ID: mdl-27346745
A series of 2(5H)-furanone-based compounds were synthesized from commercially available mucohalic acids. From the first-generation compounds, three showed inhibitory activity (10 µg/mL) of at least 35% against Mycobacterium smegmatis mc(2) 155 growth (Bioscreen C system). In screening the active first-generation compounds for growth inhibition against Mycobacterium tuberculosis H37Rv, the most active compound was identified with a minimum inhibitory concentration (MIC99 ) of 8.07 µg/mL (15.8 µM) using BACTEC 460 system. No cross-resistance was observed with some current first-line anti-TB drugs, since it similarly inhibited the growth of multidrug resistant (MDR) clinical isolates. The compound showed a good selectivity for mycobacteria since it did not inhibit the growth of selected Gram-positive and Gram-negative bacteria. It also showed synergistic activity with rifampicin (RIF) and additive activity with isoniazid (INH) and ethambutol (EMB). Additional time-kill studies showed that the compound is bacteriostatic to mycobacteria, but cytotoxic to the Chinese Hamster Ovarian (CHO) cell line. From a second generation library, two compounds showed improved anti-TB activity against M. tuberculosis H37Rv and decreased CHO cell cytotoxicity. The compounds exhibited MIC values of 2.62 µg/mL (5.6 µM) and 3.07 µg/mL (5.6 µM) respectively. The improved cytotoxicity against CHO cell line of the two compounds ranged from IC50 = 38.24 µg/mL to IC50 = 45.58 µg/mL when compared to the most active first-generation compound (IC50 = 1.82 µg/mL). The two second generation leads with selectivity indices (SI) of 14.64 and 14.85 respectively, warrant further development as anti-TB drug candidates. © 2016 IUBMB Life, 68(8):612-620, 2016.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tuberculose / Furanos / Mycobacterium tuberculosis / Antituberculosos Limite: Animals / Humans Idioma: En Revista: IUBMB Life Assunto da revista: BIOLOGIA MOLECULAR / BIOQUIMICA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: África do Sul

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tuberculose / Furanos / Mycobacterium tuberculosis / Antituberculosos Limite: Animals / Humans Idioma: En Revista: IUBMB Life Assunto da revista: BIOLOGIA MOLECULAR / BIOQUIMICA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: África do Sul